BioAtla Inc (NAS:BCAB)

$ 0.56 -0.0435 (-7.21%) Market Cap: 32.49 Mil Enterprise Value: -21.50 Mil PE Ratio: 0 PB Ratio: 1.17 GF Score: 35/100

Q3 2024 Bioatla Inc Earnings Call Transcript
Nov 07, 2024

$2.22 (+7.77%)

Earnings
Q2 2024 Bioatla Inc Earnings Call Transcript
Aug 08, 2024

$1.47 (+5.76%)

Earnings
Q1 2024 Bioatla Inc Earnings Call Transcript
May 14, 2024

$2.61 (-1.14%)

Earnings
Q4 2023 Bioatla Inc Earnings Call Transcript
Mar 26, 2024

$3.01 (+29.18%)

Earnings
Bioatla Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Bioatla Inc R&D Day Transcript
Dec 13, 2023
Q3 2023 Bioatla Inc Earnings Call Transcript
Nov 07, 2023

$1.76 (-4.35%)

Earnings
Bioatla Inc at HC Wainwright Investment Conference - New York(Pre Recorded) Transcript
Sep 11, 2023
Bioatla Inc at HC Wainwright Immune Cell Engager Virtual Conference Transcript
Aug 17, 2023
Q2 2023 Bioatla Inc Earnings Call Transcript
Aug 01, 2023

$2.88 (-3.68%)

Earnings
Bioatla Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Bioatla Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Q1 2023 Bioatla Inc Earnings Call Transcript
May 11, 2023

$3.21 (-3.02%)

Earnings
Q4 2022 Bioatla Inc Earnings Call Transcript
Mar 23, 2023

$2.3 (-1.71%)

Earnings
Q3 2022 Bioatla Inc Earnings Call Transcript
Nov 03, 2022

$6.36 (-1.40%)

Earnings
Q2 2022 Bioatla Inc Earnings Call Transcript
Aug 09, 2022

$3.61 (-3.48%)

Earnings
Q1 2022 Bioatla Inc Earnings Call Transcript
May 04, 2022

$4.08 (+6.53%)

Earnings

Bioatla Inc at HC Wainwright Investment Conference - New York(Pre Recorded) Transcript

Sep 11, 2023 / 11:00AM GMT

Release Date Price: $2.36 (-1.26%)

Transcript

Arthur He

H.C. Wainwright & Co., LLC - Analyst

Greetings everyone and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Arthur He, a senior biotech analyst with the firm. It's my great pleasure to have Dr. Jay Short, the Chairman, CEO, and Co-Founder of BioAtla joining us for a fireside chat.

BioAtla is a clinical-stage biopharmaceutical company, developing novel therapies for solid tumors based on its proprietary conditionally active biologics platform. The company currently has four drugs in clinic and multiple preclinical candidates across different modalities. To discuss the company's CAB technology and its development strategy in 2023 and beyond, I welcome Jay, to this fireside chat.

Good day, Jay.

Jay Short

BioAtla, Inc. - Chairman, CEO & Co-Founder

Pleasure to be here. Thank you, Arthur.

Arthur He

H.C. Wainwright & Co., LLC - Analyst

I'm so glad to see you accepting our invitation to talk to our audience today. So, first place, to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.